Radioligand therapy for HER2-positive cancers enters human trials for the first time

Medical Xpress

Radioligand therapy for HER2-positive cancers enters human trials for the first time

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer. ...

전문 보기

Radioligand therapy for HER2-positive cancers enters human trials for the first time

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Could psychedelic therapy have a place in end‑of‑life care? We asked doctors

Commute stress can fuel workplace conflict, but research suggests a simple fix

Stress-linked gut viruses may help tumors evade the immune system

Medical Xpress의 다른 기사

Climate-anxious youth from poorer countries 'unheard' due to digital disconnection, says study

AI framework helps identify new targets for CAR T cell therapy

As Northern Hemisphere temperatures soar, a new app shows players' heat risk for sport